Answers are grounded in this paper and cite their sources.
Acalabrutinib significantly improved PFS compared with I-R or B-R and has an acceptable safety profile in patients with R/R CLL.
No takes yet. Share an insight, caveat, or question.
Ghia et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: